News coverage about LeMaitre Vascular (NASDAQ:LMAT) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. LeMaitre Vascular earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.7976652064662 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- LeMaitre Vascular Inc Forecasted to Earn Q4 2018 Earnings of $0.28 Per Share (LMAT) (americanbankingnews.com)
- LeMaitre Vascular (LMAT) Upgraded at BidaskClub (americanbankingnews.com)
- Insider Selling: LeMaitre Vascular Inc (LMAT) Chairman Sells 30,000 Shares of Stock (americanbankingnews.com)
- LeMaitre Vascular Inc (LMAT) Shares Sold by Ranger Investment Management L.P. (americanbankingnews.com)
LeMaitre Vascular (NASDAQ:LMAT) traded up $0.24 during trading on Tuesday, reaching $37.33. 6,280 shares of the company’s stock traded hands, compared to its average volume of 125,952. The company has a market capitalization of $713.02, a P/E ratio of 43.74, a PEG ratio of 2.53 and a beta of 0.55. LeMaitre Vascular has a 1-year low of $22.16 and a 1-year high of $39.88.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.75%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. The ex-dividend date of this dividend is Wednesday, March 21st. LeMaitre Vascular’s dividend payout ratio is 25.88%.
Several analysts have weighed in on LMAT shares. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Thursday, December 28th. BidaskClub downgraded shares of LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 27th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a research note on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $34.00.
In other news, CEO George W. Lemaitre sold 42,036 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $35.68, for a total transaction of $1,499,844.48. Following the completion of the transaction, the chief executive officer now directly owns 3,259,263 shares of the company’s stock, valued at $116,290,503.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 5,700 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total transaction of $202,692.00. Following the transaction, the chief executive officer now directly owns 3,259,263 shares of the company’s stock, valued at $115,899,392.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 137,736 shares of company stock valued at $4,866,186. Insiders own 23.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect LeMaitre Vascular (LMAT) Stock Price” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-lemaitre-vascular-lmat-stock-price/2023788.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.